19888-56-3 Usage
Description
Flumethasone pivalate, commonly known as fluazacort, is a synthetic glucocorticoid with potent anti-inflammatory and immunosuppressive properties. It is a derivative of the naturally occurring hormone cortisol, which plays a crucial role in the body's response to stress and regulation of various physiological processes. Fluazacort is characterized by its ability to alleviate inflammation, suppress the immune system, and reduce the severity of allergic reactions.
Uses
Used in Pharmaceutical Industry:
Flumethasone pivalate is used as an anti-inflammatory agent for the treatment of various skin diseases. It is particularly effective in managing conditions such as eczema, dermatitis, psoriasis, and other inflammatory skin disorders. The application of fluazacort helps to reduce redness, swelling, itching, and discomfort associated with these conditions, promoting faster healing and improved skin health.
Used in Dermatology:
In the field of dermatology, fluazacort is utilized as a topical medication to provide targeted relief for skin inflammation and irritation. Its potent anti-inflammatory properties make it an ideal choice for treating a wide range of skin conditions, including allergic reactions, contact dermatitis, and other inflammatory skin disorders. By reducing inflammation and suppressing the immune response, fluazacort helps to alleviate the symptoms and promote the healing process.
Used in Ophthalmology:
Flumethasone pivalate is also used in the field of ophthalmology as an anti-inflammatory agent for the treatment of eye conditions such as uveitis, iritis, and postoperative inflammation following ocular surgery. Its ability to reduce inflammation and suppress the immune system makes it an effective treatment option for these conditions, helping to minimize discomfort and promote a faster recovery.
Used in Veterinary Medicine:
In veterinary medicine, fluazacort is employed as an anti-inflammatory and immunosuppressive agent for the treatment of various skin and eye conditions in animals. Its potent anti-inflammatory properties make it an effective treatment option for managing skin disorders such as allergies, dermatitis, and other inflammatory conditions in pets. Additionally, it is used to treat eye inflammation and postoperative complications in animals, ensuring a faster recovery and improved quality of life.
Originator
Azacortid,Richter,Italy,1975
Manufacturing Process
To a solution of 2.4 g of pregna-1,4,9(11)-triene-21-ol-3,20-dione-[17α,16α-
d]-2'-methyloxazoline 21-acetate in 24 ml of tetrahydrofuran, 12.8 ml of 0.46
N perchloric acid are added at 15°C under stirring. N-bromoacetamide (1.1 g)
is then added to the mixture which is kept far from light, and stirred for 4
hours at room temperature. After lowering the temperature to 10°C, a
saturated solution of sodium bisulfite is added in order to decolorize the
mixture, which is then poured into 120 ml of ice water. A product separates,
which is collected by filtration, washed with water and then dried, thus
obtaining 2.81 g of crude 9α-bromo-pregna-1,4-diene-11β,21-diol-3,20-dione-
[17α,16α-d]-2'-methyloxazoline-21-acetate (yield 93%), MP 175°C to 176°C.
An amount of 2.75 g of 9α-brorno-pregna-1,4-diene-11β,21-diol-3,20-dione-
[17α,16α-d]-2'-methyloxazoline-21-acetate is dissolved under nitrogen in 137
ml of a mixture methanol:chloroform (3:2). The solution is put in ice bath and
5.5 ml of 1 N NaOH are then added within 10 minutes followed by 5.5 ml
within the next 40 minutes. A strong stirring is provided for 2 hours and the
temperature is kept between 0°C and 5°C, then the pH is adjusted to 7 to 8
with glacial acetic acid. The solvent is evaporated in vacuo to 20 ml of volume
of solution, that is poured into ice water (130 ml). The product is collected by
filtration, washed with water and dried. Yield: 1.6 g (80%), MP 221°C to
222°C. It is pregna-1,4-diene-9β,11β-epoxy-21-ol-3,20-dione-[17α,16α-d]-2'-
methyloxazoline.An amount of 1 g of the above product is dissolved in 9.4 ml of a mixture
obtained by mixing 4.67 ml of hydrofluoric acid with 8.5 ml of tetrahydrofuran
at the temperature of 0°C. This solution is stirred for 20 hours at the same
temperature, then under strong stirring and cooling 20 ml of tetrahydrofuran
are added. The solution is subsequently neutralized by the addition of 24 g of
sodium bicarbonate followed by 1 g of sodium sulfate. The inorganic
substance is collected and washed with ethyl acetate. The filtrate is
evaporated to dryness and the product is crystallized from acetone: 0.65 g
(yield 61%) of pregna-1,4-dien-9α-fluoro-11β,21-diol-3,20-dione-[17α,16α-d]-
2'-methyloxazoline are obtained, MP 241°C to 244°C [α]D = +83.5 (c. 0.5,
CHCl3).The 21-acetate has MP 252°C to 255°C [α]D = +54.8 (c. 0.5, CHCl3).
Therapeutic Function
Antiinflammatory
Check Digit Verification of cas no
The CAS Registry Mumber 19888-56-3 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,9,8,8 and 8 respectively; the second part has 2 digits, 5 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 19888-56:
(7*1)+(6*9)+(5*8)+(4*8)+(3*8)+(2*5)+(1*6)=173
173 % 10 = 3
So 19888-56-3 is a valid CAS Registry Number.
InChI:InChI=1/C25H30FNO6/c1-13-27-25(20(31)12-32-14(2)28)21(33-13)10-18-17-6-5-15-9-16(29)7-8-22(15,3)24(17,26)19(30)11-23(18,25)4/h7-9,17-19,21,30H,5-6,10-12H2,1-4H3/t17-,18-,19-,21+,22-,23-,24-,25+/m0/s1
19888-56-3Relevant articles and documents
Method for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor
-
, (2008/06/13)
Methods for reducing or preventing transplant rejection in the eye of an individual are described, comprising: a) performing an ocular transplant procedure; and b) implanting in the eye a bioerodible drug delivery system comprising an immunosuppressive agent and a bioerodible polymer.
